Gsα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways

Girish Ramaswamy1,2, Hyunsoo Kim3, Deyu Zhang1,2, Vitali Lounev1,2, Joy Y. Wu4, Yongwon Choi3, Frederick S. Kaplan1,2,5, Robert J. Pignolo6 & Eileen M. Shore1,2,7

Skeletal bone formation and maintenance requires coordinate functions of several cell types, including bone forming osteoblasts and bone resorbing osteoclasts. Gsα, the stimulatory subunit of heterotrimeric G proteins, activates downstream signaling through cAMP and plays important roles in skeletal development by regulating osteoblast differentiation. Here, we demonstrate that Gsα signaling also regulates osteoclast differentiation during bone modeling and remodeling. Gnas, the gene encoding Gsα, is imprinted. Mice with paternal allele deletion of Gnas (Gnas+/-p−) have defects in cortical bone quality and strength during early development (bone modeling) that persist during adult bone remodeling. Reduced bone quality in Gnas+/-p− mice was associated with increased endosteal osteoclast numbers, with no significant effects on osteoblast number and function. Osteoclast differentiation and resorption activity was enhanced in Gnas+/-p− cells. During differentiation, Gnas+/-p− cells showed diminished pCREB, β-catenin and cyclin D1, and enhanced Nfatc1 levels, conditions favoring osteoclastogenesis. Forskolin treatment increased pCREB and rescued osteoclast differentiation in Gnas+/-p− by reducing Nfatc1 levels. Cortical bone of Gnas+/-p− mice showed elevated expression of Wnt inhibitors sclerostin and Sfrp4 consistent with reduced Wnt/β-catenin signaling. Our data identify a new role for Gsα signaling in maintaining bone quality by regulating osteoclast differentiation and function through cAMP/PKA and Wnt/β-catenin pathways.

Embryonic and early postnatal skeletal growth predominantly occurs through bone modeling, with bone resorption and formation occurring independently of each other to control bone size and shape. After skeletal development is complete, bone remodeling occurs throughout life with resorption and formation balanced at the bone surfaces in order to repair and maintain skeletal homeostasis1–3. However, during inflammation, diseases such as osteoporosis, and cancer metastasis, the balance between bone formation by osteoblasts and resorption by osteoclasts is shifted to increased resorption leading to reduced or poor quality bone4,5. Therefore, it is imperative to understand how osteoclast differentiation and function are regulated in order to improve therapeutic approaches.

Bone modeling and remodeling are precisely coordinated through interactions and regulation by multiple genes and signaling pathways including GNAS, which encodes the α-subunit of stimulatory G-protein (Gsα) of adenylyl cyclase and activates cAMP signaling. Gsα deletion in osteogenic lineage cells expressing osterix and collagen1 has demonstrated that Gsα plays important roles during skeletal development by regulating mesenchymal cell commitment, osteoblast differentiation, and mineralization without affecting osteoclast function6–9. Recent studies have also suggested that cAMP levels are regulated by several mechanisms including Wnt signaling,

1Department of Orthopaedic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 2Center for Research in FOP and Related Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 3Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 4Division of Endocrinology, Stanford University School of Medicine, Stanford, CA 94305, USA. 5Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. 6Division of Geriatric Medicine and Gerontology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 7Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Correspondence and requests for materials should be addressed to E.M.S. (email: shore@mail.med.upenn.edu)

Received: 19 December 2016
Accepted: 17 February 2017
Published: 24 March 2017
adenyl cyclase, and Ca\(^{2+}\)/Calmodulin-dependent kinases to delicately control osteoclastogenesis\(^{10,11}\). In addition, in fibrous dysplasia, a clinical condition in which activating Gs\(\alpha\) mutations cause elevated cAMP levels, increased osteoclasts occur primarily in response to osteoblast secretion of interleukin-6\(^{12,13}\). There has been no evidence of a direct role for Gs\(\alpha\) in osteoclast differentiation and function, and the impact of Gs\(\alpha\) on skeletal bone quality during modeling and remodeling remains insufficiently understood.

The GNAS gene is a complex locus that expresses multiple transcripts\(^{14-16}\). The GNAS locus is imprinted, expressing some transcripts specifically from the paternally-inherited allele and others from the maternally-inherited allele. Gs\(\alpha\) mRNA is bi-allelically expressed in most cells\(^{17}\). These different allele-specific expression patterns are reflected in human diseases and mouse models that are phenotypically distinct depending on the allele carrying a GNAS inactivating mutation\(^{18,19}\). Mice with paternally-inherited heterozygous deletion of either Gs\(\alpha\) exon 1 or exon 2 have shorter body lengths and lower body weights, while mice with maternal inheritance of the deletion of either of the exons are short but obese\(^{20}\). These data suggested that heterozygous GNAS inactivation impacts skeletal bone by affecting growth plate development and bone formation. But how Gs\(\alpha\) deletion affects skeletal bone quality during modeling and remodeling, and whether these effects differ with paternal and maternal inheritance of the mutation, has not been examined.

In this study, we investigated the effects of heterozygous GNAS inactivation in mice on skeletal bone during modeling and remodeling. We examined trabecular and cortical bone from mice with paternal or maternal inheritance of Gs\(\alpha\) deletion, and the roles of Gs\(\alpha\) signaling on osteoblast and osteoclast formation and function. Our data reveal that heterozygous Gnas inactivation negatively affects cortical bone quality, with mutation of the paternal allele causing more severe effects than maternal mutations. We further determined that paternally inherited Gs\(\alpha\) deletion alters cortical bone maintenance not through effects on osteoblasts and bone formation, but through enhanced osteoclast differentiation and increased bone resorption, and that these effects are mediated by Gs\(\alpha\) signaling via cAMP/PKA and Wnt/\(\beta\)-catenin pathways.

**Results**

**Paternal inheritance of heterozygous Gnas inactivation adversely affects cortical bone quality during bone modeling and remodeling.** To determine the role of Gs\(\alpha\) signaling on skeletal bone quality, we used an established mouse model of heterozygous Gnas inactivation\(^{20}\). Since Gnas is an imprinted locus, we examined mice with inactivation of the paternally-inherited Gnas allele (Gnas\(^{m\,-/-}\)) and the maternally-inherited Gnas allele (Gnas\(^{m+/m}\)). qRT-PCR of mRNA from cortical bone confirmed significant reduction in Gs\(\alpha\) expression in both Gnas\(^{m\,-/-}\) and Gnas\(^{m+/m}\) mice (Fig. 1a).

In most mouse strains, rapid accrual of bone occurs until 3 months of age, stabilizes by 6–8 months, and then is maintained by remodeling\(^{21}\). To evaluate the effects of heterozygous Gnas deletion on adult bone remodeling, we analyzed mice at 3 and 9 months of age. At both ages, Gnas\(^{m\,-/-}\) mice weighed less and were shorter (body and femur length were measured; femur length is reported in this study) than WT controls while Gnas\(^{m+/m}\) mice had increased body weight with no difference in femur length (Supplementary Table 1), consistent with reported results\(^{20}\). Previously, histomorphometry of distal femurs in 3-month-old animals had identified no differences vs. controls in trabecular bone volume fraction or osteoblast function in either Gnas\(^{m\,-/-}\) or Gnas\(^{m+/m}\) mice\(^{22}\). Trabecular microarchitecture was not investigated in detail and no analysis of cortical bone was performed\(^{22}\). To examine trabecular microarchitectue, distal metaphyseal femurs of 3- (Supplementary Table 1) and 9-month-old mice were examined by \(\mu\)CT (Fig. 1 and Supplementary Table 1). Overall, trabecular bone volume fraction (BV/TV) and microarchitecture (Fig. 1b,c and Supplementary Table 1) in distal femurs showed no significant differences at both ages in Gnas\(^{m\,-/-}\) and Gnas\(^{m+/m}\) mice compared to littermate controls, consistent with previous results\(^{20}\), however trends of marginal reduction, notably trabecular BV/TV and trabecular thickness, were observed in Gnas\(^{m\,-/-}\) mice. The trabecular bone of lumbar vertebrae (data not shown) also appeared unaffected in both paternally- and maternally-inherited Gnas mutants compared to controls.

Cortical bone \(\mu\)CT analyses of mid-diaphyses of adult 3- and 9-month-old Gnas\(^{m+/m}\) femurs revealed significantly increased total cortical bone volume as well as greater periosteal and endosteal circumference, consistent with the increased body weight of these mutants (Fig. 1f and Supplementary Table 1) relative to WT. No differences in cortical thickness or cortical bone volume fraction were observed (Fig. 1b,d,e). In contrast, Gnas\(^{m\,-/-}\) mice showed significant reductions in total cortical bone volume, cortical thickness, and cortical bone volume fraction at both 3 (data not shown) and 9 months (Fig. 1b,d,e and Supplementary Table 1). A larger endosteal circumference with no change in periosteal circumference suggested an increase in endosteal resorption in Gnas\(^{m\,-/-}\) mice compared to WT (Fig. 1f). Cortical porosity was marginally increased in the Gnas\(^{m\,-/-}\) mice at both ages, but not statistically significant (Supplementary Table 1). Gnas\(^{m\,-/-}\) femurs at both ages were weaker by three-point bending tests, with significant reductions in peak load and stiffness compared to WT; bone strength was unaffected in Gnas\(^{m+/m}\) mice at either age (Fig. 1g,h and Supplementary Table 1). These results indicated that paternal-allele inactivation of Gnas affects cortical bone quality during stages of adult bone remodeling.

To determine the effects of Gnas inactivation on early skeletal development and bone modeling, we examined cortical bone in 2-week-old mice by \(\mu\)CT and mechanical testing. As in older mice, no statistically significant differences in trabecular bone were found although trends of reduced BV/TV and trabecular thickness were observed in Gnas\(^{m\,-/-}\) mice. However, in contrast to older mice (Fig. 1f), both Gnas\(^{m\,-/-}\) and Gnas\(^{m+/m}\) young mice showed cortical bone defects, with significant decreases in cortical thickness and bone volume fraction (Fig. 2a–c, Supplementary Table 1). At this age, both Gnas\(^{m\,-/-}\) and Gnas\(^{m+/m}\) mice were lower in body weight and femur length compared to WT, with paternally inherited mutants showing greater reduction than the maternal allele mutants. Using three-point bending tests, femurs from both mutants showed significant reductions in stiffness and peak load (Supplementary Table 1) consistent with the \(\mu\)CT data.

Collectively, these results show that although deletion of either parental Gnas allele affects cortical bone during modeling, only inactivation of the paternally-inherited allele impacts cortical bone quality during remodeling.
marker osterix (Osx-Cre;*Gnas+/p−* and *Gnas−/−*). However, there was no statistical difference between WT and mutants comparing to WT by qRT-PCR. There was no statistical difference between WT and mutants comparing to WT by qRT-PCR. 

Representative 3D μCT images of (top) trabecular and (bottom) cortical bone. (c) No differences in trabecular bone volume fraction were observed between the groups. Decreased (d) cortical bone volume fraction, (e) cortical thickness and (g) stiffness and (h) peak load in *Gnas+/p−* mice but not *Gnas−/−* mice as compared to WT. (f) Endosteal circumference (Endo) measured at the femoral mid-shaft is increased with no change in periosteal circumference (Peri) in *Gnas+/p−* mice while both are increased in *Gnas−/−* mice. Data represent mean ± SD. N = 13 WT, 7 *Gnas+/p−* and 5 *Gnas−/−* animals. *p < 0.05, **p < 0.01.

**Osteoblast numbers and function are unaffected in *Gnas+/p−* mice.** Several studies demonstrated that ablation of Gsα signaling causes skeletal defects, including lower trabecular and cortical bone volume, due to effects on osteoblasts and bone formation6,8. These data were mainly observed in mice with Gsα deletion specifically in cells of the osteoblast lineage.

To investigate skeletal bone effects of heterozygous Gnas inactivation in osteoblasts, we used conditional Gnas heterozygous mice with paternal or maternal allele Gsα deletion and Cre expression driven by the early osteoblast marker osterix (Osx-Cre; *Gnas+/p−* and Osx-Cre; *Gnas−/−*). Unlike previous studies in Gnas null osteoblasts, μCT analyses revealed no differences at 6 weeks of age in either trabecular or cortical bone (Supplementary Figure 1a,b) in these mutants compared to control mice (*Gnas+/+, *Gnas+/−* and Osx-Cre; *Gnas+/−*).

To determine potential contributions of osteoblast numbers and function to our observed cortical bone defects in 2-week-old mutant mice, we quantified osteoblasts and mineral apposition rates (MAR). While both parameters in *Gnas+/p−* mice were similar to WT controls, *Gnas−/−* mice showed a marginal but statistically significant decrease in both osteoblast number and MAR compared to WT (Fig. 2d–g). This suggested that paternally and maternally inherited Gsα mutants affect cortical bone during development differently and support that cortical bone defects in *Gnas+/p−* mice were not due to effects in osteoblasts but possibly to effects on other cell types.

**Gnas+/p−** mice show increased endosteal osteoclasts during remodeling.** Cortical bone remodeling is a balance between osteoblast and osteoclast activity. Since osteoblast numbers and function were unaffected in parental Gnas mutants, we hypothesized that cortical bone defects in these mice could be due to altered osteoclasts. To determine osteoclast numbers, femurs from WT and *Gnas+/p−* and *Gnas−/−* mutants at 2 weeks, and 3 and 9 months of age were stained with TRAP and numbers of TRAP positive multi-nucleated osteoclasts along the cortical surface were quantified. At 2 weeks of age, when bone modeling is occurring, TRAP staining was primarily observed on the periosteal surface, and no differences among the genotypes were detected (data not shown). At 3 months of age, the numbers of TRAP positive osteoclasts were significantly elevated in *Gnas+/p−* mice (Fig. 3a,c) while *Gnas−/−* were similar to WT. At 9 months of age (Fig. 3b), the numbers of TRAP positive osteoclasts observed in all genotypes along the endosteal surface were higher than at 3 months. *Gnas−/−* femurs showed no differences in numbers of TRAP positive multi-nucleated osteoclasts compared to WT as was found at 3 months, while *Gnas+/p−* mice showed a dramatic increase in endosteal osteoclast numbers (Fig. 3c), consistent with the cortical bone defects detected in *Gnas+/p−* mice. No differences among the genotypes were observed for osteoclast numbers on trabecular bone surfaces (Supplementary Figure 2). These data suggest that inactivation of
the paternally-inherited allele of Gnas increases osteoclast numbers and enhances endosteal resorption resulting in cortical bone loss.

**Paternal allele Gnas inactivation enhances osteoclast differentiation and resorption in vitro.** Since only Gnas\(^{+/p-}\) but not Gnas\(^{m/-}\) mice showed persistent defects in cortical bone quality concomitant with
increase in endosteal osteoclasts, we investigated whether paternal allele Gnas inactivation has a direct effect on either the osteoclast progenitor population or osteoclast differentiation and function. In order to study the progenitor population, osteoclast precursors were counted from the bone marrow of WT and Gnas⁺/− mice at 7–9 weeks of age by flow cytometry⁰². The numbers of osteoclast precursor cells, namely the CD3⁻ CD45R⁻ CD11b⁻/low CD115high population, were the same in mutant and WT bone marrow (Supplementary Figure 3) indicating that cortical bone defects in Gnas⁺/− mice are not caused by increased osteoclast precursors in the bone marrow.

Upon differentiation to osteoclasts in vitro, bone marrow macrophages (BMM) from Gnas⁺/− produced significantly more TRAP positive multi-nucleated (≥3 nuclei) osteoclasts at 2 and 3 days of differentiation compared to WT (Fig. 4a and b). qRT-PCR confirmed that Gsα expression was significantly decreased in the cells from Gnas⁺/− cells during osteoclast differentiation relative to WT (Fig. 4e). cAMP levels showed trends of reduction in Gnas⁺/− cells as compared to WT cells at day 3 of osteoclast differentiation. Data represent mean ± SD. Experiments were performed at least 3 times with n = 2–3 animals per group per experiment. Total of 5–7 animals per group from 3 experiments used for quantification. For osteoclast differentiation and pit formation, cells were seeded in triplicates in 96-well plate and on bone slices respectively. For pit formation, resorption area mean of WT was set to 1. *p < 0.05; **p < 0.01.

Figure 4. Paternal inheritance of Gnas inactivation enhances osteoclast differentiation and resorption activity of osteoclasts. (a) Differentiation of bone marrow macrophages (BMMs) from 7–9 week old WT and Gnas⁺/− mice into osteoclasts. (b) Quantitation of TRAP⁺ multi-nucleated cells (≥3 nuclei) at days 1–3 of differentiation showed increased Gnas⁺/− osteoclasts at days 2 and 3 of differentiation. (c) Osteoclasts differentiated from BMMs were seeded on bone slices for 48 h and (d) the relative resorption area measured; resorption activity was greater with Gnas⁺/− osteoclasts compared to WT. (e) mRNA expression of Gsα was reduced over time in Gnas⁺/− cells during osteoclast differentiation. β2-microglobulin was used for normalization and WT values were set to 1. (f) pCREB was lower during osteoclast differentiation in Gnas⁺/− cells as compared to WT cells. (g,h) Nfatc1 from whole cell lysate was significantly elevated in Gnas⁺/− cells as compared to WT cells at day 3 of osteoclast differentiation. Data represent mean ± SD. Experiments were performed at least 3 times with n = 2–3 animals per group per experiment. Total of 5–7 animals per group from 3 experiments used for quantification. For osteoclast differentiation and pit formation, cells were seeded in triplicates in 96-well plate and on bone slices respectively. For pit formation, resorption area mean of WT was set to 1. *p < 0.05; **p < 0.01.
Decreased cAMP/PKA pathway, increased Nfatc1 and enhanced osteoclast differentiation in Gnas\(^{+/p}\) mice.

Gs\(\alpha\) signals primarily through adenylyl cyclase and the cAMP/PKA pathway. Recent studies implicated this pathway as inhibitory to osteoclast differentiation by phosphorylating Nfatc1, an important transcription factor for osteoclast differentiation. Adenylyl cyclase activity is decreased in Gnas\(^{+/p}\) mice, raising the possibility that decreased cAMP leads to decreased phospho-Nfatc1 and increased osteoclasts. To investigate this mechanism, we analyzed protein levels of pCREB, a downstream activator of the cAMP/PKA pathway during osteoclast differentiation. We found that pCREB protein levels were marginally reduced at day 0 and significantly reduced at day 1 of osteoclast differentiation in cells from Gnas\(^{+/p}\) mice (Fig. 4f and Supplementary Figures 4a,b). We investigated whether this decreased cAMP signaling is associated with altered Nfatc1 levels and determined that both total and nuclear Nfatc1 protein was highly up-regulated at day 3 of osteoclast differentiation in Gnas\(^{+/p}\) osteoclasts compared to WT (Fig. 4g,h and Supplementary Figures 4d,e), suggesting that paternal Gnas allele deletion reduces pCREB during early differentiation and enhances Nfatc1 at a protein level to impact osteoclastogenesis.

Forskolin inhibits Nfatc1-induced osteoclastogenesis by elevating adenylyl cyclase and PKA activity. We therefore hypothesized that treatment with forskolin would rescue the increased osteoclast differentiation by Gnas\(^{+/p}\) cells. In order to test this, we induced osteoclast differentiation of WT and Gnas\(^{+/p}\) osteoclast precursor cells in the presence or absence of forskolin. Treatment of Gnas\(^{+/p}\) cells with forskolin abolished the increase in TRAP\(^+\) multi-nucleated osteoclasts to levels comparable to WT (Fig. 5a,b). In addition, forskolin increased pCREB (Fig. 5c) and decreased Nfatc1 (Fig. 5d) to levels comparable to WT. Together, these results demonstrate that activation of PKA rescues pCREB, and regulates Nfatc1 levels and osteoclast differentiation in Gnas\(^{+/p}\) cells.

\(\beta\)-catenin and its target cyclin D1 are reduced in Gnas\(^{+/p}\) mice.

Wnt signaling inhibits osteoclast differentiation through canonical \(\beta\)-catenin-dependent pathways and non-canonical pathways. \(\beta\)-catenin and its transcriptional target cyclin D1 have been shown to play biphasic roles during osteoclast proliferation and differentiation. Their expression is required for osteoclast precursor proliferation, and both are activated by M-CSF but suppressed by RANKL during osteoclast differentiation. Since mice with Gs\(\alpha\) deletion in osteoblasts and osteocytes exhibit decreased Wnt/\(\beta\)-catenin signaling, we examined whether reduction in Wnt/\(\beta\)-catenin signaling in Gnas\(^{+/p}\) mice could lead to increased osteoclast differentiation. To determine the levels of Wnt/\(\beta\)-catenin signaling, total \(\beta\)-catenin from cell lysates during osteoclast differentiation were detected by immunoblot. Under normal circumstances, RANKL suppresses \(\beta\)-catenin and cyclin D1 during osteoclast differentiation. Indeed, we found that both WT and Gnas\(^{+/p}\) cells showed reduction in \(\beta\)-catenin (data not shown) and cyclin D1 in response to RANKL. However, comparison of WT and Gnas\(^{+/p}\) cells showed that \(\beta\)-catenin and cyclin D1

Figure 5. Forskolin (Fsk) rescues the osteoclast differentiation phenotype of cells from Gnas\(^{+/p}\) mice. (a,b) Forskolin treatment during osteoclast differentiation rescued the increased osteoclast numbers in Gnas\(^{+/p}\) mice. (c,d) Forskolin treatment of Gnas\(^{+/p}\) cells increased pCREB (c) and reduced Nfatc1 (d) to levels comparable to WT. Experiments were performed at least 3 times with \(n = 1–2\) animals per group per experiment. Total of 5 animals per group used for quantification. *\(p < 0.05\).
Wnt inhibitors Sost and Sfrp4 were up-regulated in both 3 and 9-month-old mice. While there was no difference in expression of the Wnt target gene Lef1 (data not shown), mRNA levels of the Wnt targets and inhibitors from the diaphyses of femurs and tibiae from 3- and 9-month-old mice was quantified. *p < 0.05.

were more greatly decreased in Gnas+/p− cells than WT (Fig. 6a,b), supporting that inappropriately low levels of β-catenin and its downstream cyclin D1 enhance osteoclast differentiation in Gnas+/p− mice.

To determine whether Wnt/β-catenin signaling is altered in skeletal bone cells of Gnas+/p− mice, expression of Wnt targets and inhibitors from the diaphyses of femurs and tibiae from 3- and 9-month-old mice was quantified. While there was no difference in expression of the Wnt target gene Lef1 (data not shown), mRNA levels of the Wnt inhibitors Sost and Sfrp4 were up-regulated in both 3 and 9-month-old Gnas+/p− mice (Fig. 6c–e). A higher percent of osteocytes positive for Sclerostin in femurs of 3-month-old Gnas+/p− mice was detected by immunohistochemistry (Fig. 6f,g). Collectively, these data support that an overall increase in Wnt inhibitors causes a decrease in β-catenin/cyclin D1 leading to increased osteoclastogenesis in paternally-inherited Gnas inactivation mutants.

Discussion

Human diseases caused by GNAS mutations provide insight into the roles of GNAS in bone formation and have identified regulatory functions in osteoblasts. In progressive osseous heteroplasia (POH) and pseudohypoparathyroidisms 1A (PHP1A), heterozygous GNAS/Gnas inactivation and decreased Goα signaling cause heterotopic ossification (extra-skeletal bone formation) in soft tissues such as subcutaneous fat and muscle15,24,30,31. Fibrous dysplasia (FD), caused by somatic activating mutations in GNAS, is characterized by woven bone lesions in skeletal bone due to defective osteoblast differentiation12–14; FD also shows increased osteoclastic bone resorption at the site of these lesions that is not a direct effect of Goα signaling12–15. The underlying mechanisms for these phenotypic differences are incompletely understood, and may be influenced by genomic and tissue-specific imprinting at the GNAS locus and/or differences in GNAS transcript expression.

![Figure 6. Wnt/β-catenin-mediated cyclin D1 signaling is downregulated in Gnas+/p− mice.](image-url)
In our study, heterozygous Gnas knockout mice with paternal (Gnas\(^{+/p}\)) vs. maternal (Gnas\(^{m/-}\)) inheritance of a Gnas deletion showed similar defects in cortical bone quality and strength during early development (bone modeling). This reduction in bone quality persisted during adult bone remodeling in Gnas\(^{+/p}\) mice, however Gnas\(^{m/-}\) mice recovered, showing bone qualities similar to Gnas\(^{+/p}\) control mice at adult bone remodeling stages.

Gsα signaling activates cAMP which phosphorylates PKA and CREB\(^{42,43}\). Previous studies of homozygous deletion of Gsα in osterix-expressing osteoblast precursors revealed adverse effects on both trabecular and cortical bone due to defective mesenchymal progenitor commitment to osteoblasts and terminal osteoblast differentiation\(^{9,8}\). Gsα deletion in col1α1-expressing osteoblasts showed decreased TRAP positive osteoclasts at the endocortical bone surface leading to an increase in cortical thickness; however, this analyses was limited to the bone modeling stage in newborn mice\(^9\). Furthermore, activation of cAMP and phosphorylation of PKA and CREB in osteoblasts was found to activate osteoclasts by increasing RANKL and inhibiting OPG (a decoy receptor for RANKL that impedes osteoclastogenesis)\(^{20,41}\). None of these studies examined the effects of Gsα signaling on osteoclast differentiation and function or its impact on postnatal bone quality during bone remodeling.

Given this previous evidence that Gsα affects osteoblasts and bone formation, we examined whether the reduced skeletal bone quality in Gnas mutant mice was due to impaired osteoblast numbers or function. We found no significant effects on osteoblast number and function in the paternal mutants while maternal mutants unexpectedly showed a marginal reduction in both parameters. Although statistically significant, these effects in maternal Gnas mutants are small and insufficient to draw conclusions about functional effects. Future studies to further investigate proliferation and osteoblast differentiation with cells from WT and Gnas\(^{m/-}\) are necessary to determine the mechanisms underlying these in vitro osteoblast changes.

By contrast, endosteal osteoclast numbers were increased in vivo in Gnas\(^{+/p}\) but not in Gnas\(^{m/-}\) mice when compared to WT. However, in vitro differentiation of either Gnas\(^{+/p}\) or Gnas\(^{m/-}\) bone marrow macrophages to osteoclasts was enhanced. Gnas mutant osteoclasts also had increased bone resorption activity in vitro, with paternal mutants showing a more dramatic increase than the maternal mutants. These results suggest that haploinsufficiency of Gsα leads to increases in osteoclastogenesis in vitro, but additional factors in vivo (such as sclerostin which is increased in Gnas\(^{+/p}\) cortical bone (Fig. 6c–g) and decreased in Gnas\(^{m/-}\) cortical bone (Supplementary Figure 6b)) and imprinting effects may contribute to the persistent cortical bone phenotype and increased endosteal osteoclasts that we observe only in the paternal mutants. Although our in vitro experiments suggest a cell-autonomous role for Gsα in osteoclasts, future studies ablating Gsα specifically in the osteoclast lineage (using LysozymeM-Cre\(^{42}\) or RANK-Cre\(^{45}\)) would further elucidate the role of Gsα in osteoclast differentiation and function as well as its impact on skeletal development and remodeling.

Interactions between the Wnt signaling pathways and cAMP/PKA have been reported previously\(^{43,44}\). Wnt signaling has been established to inhibit osteoclast differentiation via canonical\(^{10,45}\) (β-catenin) and non-canonical (cAMP/PKA) pathways\(^{46}\). Wnt signaling inhibits osteoclastogenesis by stabilizing β-catenin\(^{10}\), a primary component of the canonical pathway, and also by increasing levels of OPG\(^{27,45,46}\). In addition, Wnt also enhances cAMP and PKA phosphorylation, and suppresses Nfatc1 by inhibiting its nuclear translocation and autoamplification of Nfatc1\(^{10}\). However, these reports did not directly demonstrate a role for Gsα in osteoclast differentiation. Here, we show that reduced Gnas/Gsα increased osteoclast differentiation and resorption function via cAMP/PKA and the Wnt/β-catenin pathway. Our results not only support an important role for Gsα in osteoclastogenesis but, together with previous reports\(^{10}\), also suggest crosstalk between Gsα/cAMP/PKA and canonical Wnt/β-catenin signaling pathways to regulate osteoclast differentiation.

We did not detect significant trabecular bone effects in either Gnas\(^{+/p}\) or Gnas\(^{m/-}\) mice, however our data suggested that trabecular bone may also be effected, although more mildly. The trabecular bone effects in our heterozygous germline deletion of Gsα were more subtle compared to the stronger effects in cell-specific Gnas null mouse models\(^{6,8,9,29}\) and could be due to differences in Gsα levels in cells that interact to regulate bone. Additionally or alternatively, locally-acting factors could differentially affect cortical and trabecular bone. We found that expression of Sost, a Wnt inhibitor that was recently determined to induce osteoclast formation and activity\(^{7}\), was increased in the cortical bone of Gnas\(^{+/p}\) mice, however was extremely low in trabecular bone and could not be reliably quantified (Supplementary Figure 6a); this finding has been consistently noted in published\(^{30}\) and unpublished data (J. Wu el al). If Sost levels are indeed much lower in trabecular bone, this could be an explanation for the stronger cortical bone phenotype. Further analyses of these mutants will provide information to delineate the roles of Gsα in cortical and trabecular bone.

Our data suggest that osteoclast cell autonomous effects of Gnas mutation together with extrinsic factors that act on osteoclasts influence the observed in vivo bone phenotype. This study reveals important roles for Gnas/ Gsα signaling in bone remodeling through regulation of osteoclastogenesis and osteoclast resorption activity, with potential implications for drug development approaches to treating diseases that affect cortical bone quality.

**Materials and Methods**

**Animals.** Mice with heterozygous deletion of maternal and paternal alleles of Gnas were described previously\(^{29}\). To generate mice with paternal inheritance of the deletion (Gnas\(^{+/p}\)), male mice carrying a heterozygous deletion in exon 1 of Gnas (maintained on a SvEv background) were crossed to female CD1 wild-type mice. Mice with maternal inheritance of the Gnas deletion (Gnas\(^{m/-}\)) were generated by crossing female mutant mice to male wild-type mice. In both breeding schemes, Gnas\(^{+/+}\) littermates were used as wild-type controls in all experiments. Only males were used for all experiments to minimize variability and because males were previously reported to have a more consistent phenotype\(^{30}\). All animal experiments were performed in accordance with the relevant regulations and guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC), University of Pennsylvania.
Osx1-GFP::Cre\(^{49}\) and Gs\(_{\alpha}\)(fl/fl)\(^{50}\) mice were described previously. Because these mice have a mixed genetic background (C57BL/6 and CD1), littermates were used as controls. Female conditional heterozygous mice [Osx1-GFP::Cre + Gs\(_{\alpha}\)(fl/fl)] were mated to control males (mixed background) to generate heterozygous mice with disruption of the maternal allele (Osx1-GFP::Cre + Gs\(_{\alpha}\)(fl/fl) referred to as Osx-Cre/Gnas\(_{\alpha}\)(fl/fl) in this study). Male conditional heterozygous mice were mated to wild-type females to generate heterozygous mice with disruption of the paternal allele (Osx1-GFP::Cre + Gs\(_{\alpha}\)(fl/fl) referred to as Osx-Cre; Gnas\(_{\alpha}\)(fl/fl) in this study). Control mice with Osx1-GFP::Cre [Osx1-GFP::Cre + Gs\(_{\alpha}\)(fl/fl) referred to as Osx-Cre; Gnas\(_{\alpha}\)(fl/fl) in this study] and without [Gs\(_{\alpha}\)(fl/fl) and Gs\(_{\alpha}\)(fl/fl) referred to Gnas\(_{\alpha}\)(fl/fl) and Gnas\(_{\alpha}\)(fl/fl) in this study] were also analyzed to ensure that the Osx1-GFP::Cre transgene did not confer a phenotype. Genotyping used genomic DNA isolated from tails and previously published protocols\(^{6,8,51}\). These animals were housed in the Center for Comparative Medicine at the Massachusetts General Hospital, and all experiments were approved by the hospital’s Subcommittee on Research Animal Care.

**Microcomputed tomography (\(\mu\)CT).** Femurs from 2 week, 3 month and 9 month old mice were harvested and scanned by \(\mu\)CT (\(\mu\)CT35, SCANCO Medical AG, Bruttisellen, Switzerland). For trabecular bone analysis, scans were performed at the distal femoral metaphysis 0.4 mm proximal to the growth plate. For cortical bone, mid-diaphysis of femurs were scanned. All scans were performed at a resolution of 6\(\mu\)m per slice using a \(\lambda\)-ray energy of 55 keV and an integration time of 300 ms. A total of 125 slices were analyzed using the instrument’s software.

**Mechanical testing.** Femurs from 2 week, 3 month and 9 month old mice were subjected to mechanical testing by three-point bending using a custom-made fixture\(^{52}\) on an Instron machine. Load was applied until failure and stiffness and peak load were calculated from the load-displacement data\(^{49}\). 2D cortical bone \(\mu\)CT images were incorporated into a custom developed Matlab program to determine the moment of inertia.

**Histology.** Limbs were fixed in 4% paraformaldehyde for 24–48 hours, decalcified in 10% EDTA for 7 days, processed, and embedded in paraffin. Sections of 5\(\mu\)m thickness were cut for staining. TRAP staining used the leukocyte acid phosphatase kit (Sigma 387 A). Multi-nucleated osteoclasts (\(\geq\) 3 nuclei) were counted along the endosteal surface at the femoral diaphysis and at the distal femur proximal to the growth plate. Osteoblasts were identified based on their morphology after H&E staining and counted along the endosteum at the diaphyseal region. To determine mineral apposition rate (MAR), mice were injected with calcein (15\(\mu\)g/g body weight) on postnatal day 10 and xylene orange (100\(\mu\)g/g body weight) on postnatal day 13 and sacrificed 24 hours later. MAR was calculated as the distance between the two labels along the femoral mid-diaphyseal region by the number of days between the injections.

**Immunohistochemistry.** Paraffin embedded sections were detected with Sost antibody (anti-goat; R&D systems, AF1589). Antigen retrieval was performed by treating the sections with Proteinase K (20\(\mu\)g/ml, Roche) at 37 °C for 15–20 minutes. Sections were then treated with 3% hydrogen peroxide for 10 minutes followed by blocking with 5% BSA and 10% donkey serum in 1X PBST. Sections were incubated with the Sost antibody at 4°C for 1 hour and developed using DAB chromogen (Life Technologies). Three to five images were taken along the mid-diaphyses of femur, starting from 2 mm proximal to the growth plate, and Sost positive cells were quantified. In situ hybridization of bone was performed using the Sost antisense oligonucleotide probe. Sost expression was detected with Sost antibody (anti-goat; R&D Systems). Sections were blocked with goat serum and incubated with Sost antibody (anti-goat; R&D Systems). Sections were incubated with the Sost antibody at 4°C for 1 hour and developed using DAB chromogen (Life Technologies).

**Real-time PCR.** Femur and tibiae from mice were stripped of soft tissue, ends were cut and bone marrow was flushed to obtain only the diaphyseal bone region. Cortical bone pieces were frozen in liquid nitrogen and crushed with stainless steel beads (7 mm diameter, Qiagen) using a tissue lyser (TissueLyser LT, Qiagen). RNA was then extracted with Trizol (Thermo Fisher Scientific) using manufacturer’s instructions. cDNA was prepared using High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific). Real-time qRT-PCR was performed using SYBR Green method. Primer sequences are as follows: Gs\(_{\alpha}\): 5′-GGCGGAGGCCAACAAAAGAT and 5′-TGCCGACTCTCCAGCACCCG; Sost: 5′-CCAGGGCTTTGGAGAGTACC and 5′-GCAGCTG TACTCGGACACATC; Sfrp4: 5′-AGAAGGTCCATACGTGGGAAG and 5′-GTACTCGCACTTGTTGCGA.

**Osteoclast differentiation and function.** Following our standard procedures\(^{44}\), bone marrow from 6–8 week old mice was flushed from femurs and tibiae using a 26-G needle into MEM (Gibco) with 10% fetal bovine serum and 1X antibiotics. After lysis of RBCs, cells were cultured overnight with recombinant M-CSF (Peprotech, NJ) at 5\(\mu\)g/ml. Next day, non-adherent cells were harvested and reseded with M-CSF at 30 ng/ml for 3 additional days to acquire bone marrow macrophages (BMM). After 3 days, BMM were collected and cultured with M-CSF (30 ng/ml) and RANKL (Peprotech, 150 ng/ml) at 5 × 10\(^5\) cells per well in a 6-well plate for RNA or protein and 5 × 10\(^4\) cells per well in a 96-well plate for TRAP staining.

For pit formation assays\(^{44}\), BMM were first differentiated into osteoclasts with M-CSF (30 ng/ml) and RANKL (150 ng/ml) for 3 days. Osteoclasts were then seeded at 1 × 10\(^4\) cells per slice for 48 hours and percent resorption area was determined. Mean of resorption area for WT was set to 1.

**Flow cytometry.** Bone marrow was flushed from 6–8 week old mice using 1X PBS with 2% FBS. Red blood cells were lysed using 1X RBC lysis buffer (Biolegend). Cells were washed twice in 1X PBS with 0.5% BSA, then blocked using rat IgG (TruStain fcX, Biolegend) for 10 minutes on ice. Cells (1 × 10\(^6\) cells in 100\(\mu\)l) were then detected with antibodies at 0.2\(\mu\)g per million cells for 30 minutes on ice protected from light. The antibodies used for flow cytometry to detect osteoclast precursors were the following: anti-mouse CD3\(^{+}\)-BV421 (BD Biosciences #564008), anti-mouse CD45R-Alexa Fluor488 (BD Biosciences #557669), anti-mouse CD11b-APC (BD Biosciences #553312), anti-mouse CD115-PE (BD Biosciences #565249). Flow cytometry was conducted with a LSR II (BD Biosciences) and data were analyzed using FlowJo software.
Western blot. Whole cell extracts were obtained using RIPA buffer (Sigma) while nuclear fraction was isolated using NE-PER nuclear and cytoplasmic extraction kit (ThermoFisher Scientific) along with proteinase (Sigma) and phosphatase inhibitor cocktails (Sigma). Protein samples were separated by 4–10% SDS-PAGE and transferred to nitrocellulose membranes. Blots were blocked with 5% milk in 1 X TBST, then incubated with primary antibodies overnight at 4 °C. Primary antibodies used in this study were pCREB, β-catenin, cyclin D1, GAPDH, Histone H3 (all from Cell Signaling, MA, USA) and Nfatc1 (Santa Cruz Biotechnology, CA, USA); all were used at 1:1000 dilution. Gapdh and Histone H3 were used at 1:5000 dilution. Membranes were washed 3 times in TBST and incubated in secondary antibodies conjugated to HRP at 1:6000 dilution for 1 hour at room temperature. Blots were developed and densitometry was quantified with a LI-COR C-Digit blot scanner.

cAMP Measurement. Intracellular CAMP levels were measured in macrophages from WT and Gnas<sup>+/−</sup> mice using a cAMP EIA system (GE Healthcare, Little Chalfont, UK). The assay was performed according to the manufacturer's instructions. Data were normalized to total protein and WT was set to 1.

Statistical analyses. One-way ANOVA with Tukey post-hoc tests was used for comparing WT (Gnas<sup>+/+</sup>), Gnas<sup>+/−</sup> and Gnas<sup>−/−</sup> groups for μCT and mechanical testing data. WT data from paternal and maternal litters were pooled. Two-way ANOVA with Bonferroni post-hoc tests was used for analyzing osteoclast differentiation assays. Student’s t-test or one-way ANOVA was performed to compare real time qRT-PCR, pit formation data and sclerostin immunohistochemistry data after setting littermate controls to 1 when comparing two or more than two groups respectively. p < 0.05 was considered statistically significant.

References

1. Eriksen, E. F. Cellular mechanisms of bone remodeling. Reviews in Endocrine and Metabolic Disorders 11, 219–227 (2010).
2. Seeman, E. Bone modeling and remodeling. Critical Reviews in Eukaryotic Gene Expression 19, 219–233 (2009).
3. Sims, N. A. & Martin, T. J. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKey reports 3, 481 (2014).
4. Abu-Amer, Y. Inflammation, cancer, and bone loss. Current Opinion in Pharmacology 9, 427–433 (2009).
5. Jones, D., Glimcher, L. H. & Aliprantis, A. O. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. Journal of Clinical Investigation 121, 2534–2542 (2011).
6. Jones, D., Glimcher, L. H. & Aliprantis, A. O. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. Journal of Clinical Investigation 121, 2534–2542 (2011).
7. Sinha, P. et al. Loss of Gs<sub>α</sub> early in the osteoblast lineage favors adipogenic differentiation of mesenchymal progenitors and committed osteoblast precursors. Journal of Bone and Mineral Research 29, 2414–2426 (2014).
8. Sinha, P. et al. Loss of Gs<sub>α</sub> in the postnatal skeleton leads to low bone mass and a blunted response to anabolic parathyroid hormone therapy. Journal of Biological Chemistry 291, 1631–1642 (2016).
9. Sakamoto, A. et al. Deficiency of the G-protein α<sub>subunit</sub> Gα<sub>s</sub> in osteoblasts leads to differential effects on trabecular and cortical bone. Journal of Biological Chemistry 280, 21369–21375 (2005).
10. Weiwoda, M. M. et al. Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical CAMP/PKA Pathways. Journal of Bone and Mineral Research 31, 65–75 (2016).
11. Yoon, S. H., Ryu, J. Y., Lee, Y., Lee, Z. H. & Kim, H. H. Adenylyl cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway. Journal of Bone and Mineral Research 26, 1217–1229 (2011).
12. Riminucci, M. et al. Osteoclastogenesis in fibrous dysplasia of bone: In situ and in vitro analysis of IL-6 expression. Bone 33, 434–442 (2003).
13. Chapurlat, R. D. & Orcel, P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Practice and Research: Clinical Rheumatology 22, 55–69 (2008).
14. Pignolo, R. J., Ramaswamy, G., Fong, J. T., Shore, E. M. & Kaplan, F. S. Progressive osteous heteroplasia: diagnosis, treatment, and prognosis. 37–48 (2015).
15. Turan, S. & Bastepe, M. The GNAS complex locus and human diseases associated with loss-of-function mutations or epimutations within this imprinted gene. Hormone Research Paediatrics 80, 229–241 (2013).
16. Bastepe, M. The GNAS Locue: Quintessential Complex Gene Encoding Gsα, XLAlphas, and other Imprinted Transcripts. Current genomics 6, 398–414 (2007).
17. Pagge, A., Kelsey, G. & Germain-Le, E. I. Physiological functions of the imprinted Gnas locus and its protein variants Gsα and XLαs in human and mouse. Journal of Endocrinology 196, 193–214 (2008).
18. Adegbite, N. S., Xu, M., Kaplan, F. S., Shore, E. M. & Pignolo, R. J. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. American Journal of Medical Genetics, Part A 146, 1788–1796 (2008).
19. Lebrun, M. et al. Progressive osteous heteroplasia: A model for the imprinting effects of GNAS inactivating mutations in humans. Journal of Clinical Endocrinology and Metabolism 95, 3028–3038 (2010).
20. Germain-Le, L. E. et al. A mouse model of albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology 146, 4697–4709 (2005).
21. Ke, H. Z. In vivo characterization of skeletal phenotype of genetically modified mice. Journal of Bone and Mineral Metabolism 23, 84–89 (2005).
22. Jacquin, C., Gran, D. E., Lee, S. K., Lorenzo, J. A. & Aguila, H. L. Identification of Multiple Osteoclast Precursor Populations in Murine Bone Marrow. Journal of Bone and Mineral Research 21, 61–77 (2005).
23. Kronenberg, H. M. Gs signaling in osteoblasts and hematopoietic stem cells. Annals of the New York Academy of Sciences 1192, 327–329 (2010).
24. Regard, J. B. et al. Activation of Hedgehog signaling by loss of Gnas causes heterotopic ossification. Nature Medicine 19, 1505–1512 (2013).
25. Zhang, S., Kaplan, F. S. & Shore, E. M. Different roles of Gsα and cAMP signaling during early and late stages of osteogenic differentiation. Horm Metab Res 44, 724–731 (2012).
26. Takayanagi, H. The role of NEAT in osteoclast formation. Annals of the New York Academy of Sciences 1116, 227–237 (2007).
27. Kramer, L. et al. Osteocyte Wnt-beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30, 3071–3085 (2010).
28. Wei, W. et al. Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by ~Catenin. Molecular and Cellular Biology 31, 4706–4719 (2011).
29. Pulzele, K. et al. Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling. Blood 121, 930–939 (2013).
30. Cairns, D. M. et al. Somitic disruption of Gnas in chick embryos mimics progressive osseous heteroplasia. Journal of Clinical Investigation 123, 3624–3633 (2013).
GSα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways.

How to cite this article: Ramaswamy, G. et al. GSα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways. Sci. Rep. 7, 45140; doi: 10.1038/srep45140 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017